Apixaban versus warfarin in patients with atrial fibrillation - Wikidata - awgldk - TriplyDB

Apixaban versus warfarin in patients with atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

http://www.wikidata.org/entity/Q29617563

about

New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation Stroke prevention in atrial fibrillation: latest clinical trials and guidelines Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study Dabigatran approaching the realm of heparin-induced thrombocytopenia Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences Management of antithrombotic therapy during cardiac implantable device surgery Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians The Mechanism of and Preventive Therapy for Stroke in Patients with Atrial Fibrillation How we treat bleeding associated with direct oral anticoagulants Asian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral Anticoagulants Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues Edoxaban in venous thromboembolism and stroke prevention: an appraisal Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab Emerging Tools for Stroke Prevention in Atrial Fibrillation Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review Improved Cardiovascular Disease Outcomes in Older Adults Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population Novel oral anticoagulants and the 73rd anniversary of historical warfarin Stroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Monitoring anticoagulant therapy with new oral agents The evolution of anticoagulant therapy Managing atrial fibrillation in the very elderly patient: challenges and solutions How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives Apixaban and oral implications A review of the LARIAT device: insights from the cumulative clinical experience Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis Atrial fibrillation in heart failure: what should we do?Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities

P2860

Q21132464-0E47E178-B8FA-4C5F-934F-5A6291B34142 Q21284803-724BDE9B-1E82-40DD-B1BA-6FAC571B78B4 Q22241786-0722537C-DA5A-40C3-9019-58124AFA0589 Q24197843-506586C2-4E8E-40CF-807F-D59C3F62F167 Q24200497-059A456E-F1CD-41EA-92F6-55A6EBEA2402 Q24202280-435AC920-A32A-422D-BB14-DCD974CB6040 Q24628390-E2EB32D9-D066-4606-924A-353A066F4C8C Q24658646-60A9F395-8B73-490A-9A39-5D75331DD1F1 Q26744261-FC91AB1E-77AE-49F5-B27E-D820DCF01444 Q26746062-AD2B4EDD-3607-48AD-8A1E-B2235C4D69DA Q26746160-D576F330-21BC-4D74-A739-C9E0303948BB Q26746233-495302C4-45D0-4D1A-B162-64167BA085BE Q26746917-F3BCB298-88EF-4BD0-8B7A-B9436E229D3D Q26747263-89986828-7BA0-4CCB-B8EA-4A3347A4C25D Q26748343-51F7748A-5129-4CF0-A476-27C1CA4D5EF0 Q26750467-3560C28F-0324-4972-B902-9A62A253E919 Q26750767-89F676F3-8663-4B12-84DE-D2698B0F53D3 Q26751263-8FD83982-B8D7-4446-AF64-F683BCC70F06 Q26764853-558FE402-9C4B-463B-B1C5-AE835B729283 Q26764882-B00E9572-5152-4974-AC74-BE15E7FFC5B8 Q26765023-016CEE00-7EB4-4B52-AB66-FCDD134300D3 Q26765949-B7F65A8B-A073-4353-B57B-B868B7137E16 Q26766094-96765608-1749-4696-B80F-362ECF1CCD44 Q26766354-C1F1B504-DDD6-46F0-B533-B5E545E66D4E Q26770402-03FD9843-18F8-4E8F-A3DF-5703B6BE1FA8 Q26771544-0EFB3EBE-FA01-4A2A-B570-66A8F037FFCA Q26771564-AFADE6E3-F0A4-418D-8DC8-42514D3FAA71 Q26771728-1590ECF8-D82B-4C50-BF67-CFA5C5CA1999 Q26771859-A0CC434F-09B3-4F5C-BC17-DC7D385FFD3D Q26775877-E5E7B2F9-5F35-45B4-B35D-2695448FE4DF Q26776413-372D2D11-C082-4D73-9500-C14F16A38C91 Q26778659-1AE6D466-43F9-4209-BAA3-D2D20655949E Q26780328-94CF14F1-A9DF-4A79-812A-9DC429AD7851 Q26781162-25B01219-9D85-4AA0-9DF1-AAF304144431 Q26781181-EEC2CCBF-C7D9-4CE8-91A3-DC622FDBBB51 Q26783455-F42ADA60-6A43-41B9-942B-788BB3D106A5 Q26783473-E8C2FF3C-9B41-4A5F-B7E0-2BB2C03ADD01 Q26784426-69CE87FA-A745-4747-82BA-AC6156675AC0 Q26785480-9F23F2FE-9A16-4BB1-A2CA-4CD395B70EBB Q26787046-98AC677D-4FCD-41C8-BAC6-6FD95121658B

P2860

Apixaban versus warfarin in patients with atrial fibrillation

http://www.wikidata.org/entity/Q29617563

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Apixaban versus warfarin in patients with atrial fibrillation

@ast

Apixaban versus warfarin in patients with atrial fibrillation

@en

type

label

Apixaban versus warfarin in patients with atrial fibrillation

@ast

Apixaban versus warfarin in patients with atrial fibrillation

@en

prefLabel

Apixaban versus warfarin in patients with atrial fibrillation

@ast

Apixaban versus warfarin in patients with atrial fibrillation

@en

P1433

Q29617563-1EE3C1C6-11AA-453F-87C3-F051B3931248

P1476

Q29617563-4EF0BBBC-46D5-4723-9F71-406DD0F8F1E0

P2093

Q29617563-08C210FD-1E08-4E60-BA9A-459848166D77

Q29617563-0D543B96-A16F-4D8D-973F-6A2F6FDE36E0

Q29617563-18A89D09-BA05-42EA-B5DD-491C03A19EEA

Q29617563-1BF6AF61-6256-499C-9A6D-FC57C8D1203E

Q29617563-2039BDCB-23BA-4AD5-A6BC-93582C579C7A

Q29617563-219ACB2A-B294-41B6-AD69-2F24C36AA33B

Q29617563-227DEC47-8264-4F3C-864C-8C435CCA80D2

Q29617563-2415CF35-4341-45F2-B735-E992A80374CF

Q29617563-31A80E28-E83E-46CB-A87E-FCBFE1B3B6BF

Q29617563-3D0EF5D2-2D9F-471D-849C-903070B554E2

P304

Q29617563-B2A0FBA2-B344-4E38-AADF-2B0198B4216E

P31

Q29617563-67A67FC0-A2AC-49EF-9CE8-7210189B633E

P3181

Q29617563-21B52952-28FE-48AF-992B-45E5B8954E22

P356

Q29617563-DA79A08A-9444-4D42-9448-3CA1C7B9142C

P407

Q29617563-B0658EC7-B378-4C20-BB3F-98BA0DDDED90

P433

Q29617563-F0929DDA-28CD-40B2-8F55-4DED8696F1C4

P478

Q29617563-77C55B7D-A266-417D-A389-0CCF0922BDDD

P50

Q29617563-C3A8FA59-2411-4A30-A1DC-5F01ED3A2B51

P577

Q29617563-5A3A3F10-343A-45EC-B924-A4C551010C4E

P698

Q29617563-267885F0-0AA9-402C-A571-5B64F79E788F

P921

Q29617563-FB9CA30D-2BB6-48E1-9065-94C1F7D9BC2C

P3181

P356

P1433

The New England Journal of Medicine

P1476

Apixaban versus warfarin in patients with atrial fibrillation

@en

P2093

Al-Khalidi HR

http://www.w3.org/2001/XMLSchema#string

Alexander JH

http://www.w3.org/2001/XMLSchema#string

Ansell J

http://www.w3.org/2001/XMLSchema#string

Atar D

http://www.w3.org/2001/XMLSchema#string

Avezum A

http://www.w3.org/2001/XMLSchema#string

Bahit MC

http://www.w3.org/2001/XMLSchema#string

Diaz R

http://www.w3.org/2001/XMLSchema#string

Easton JD

http://www.w3.org/2001/XMLSchema#string

Ezekowitz JA

http://www.w3.org/2001/XMLSchema#string

Flaker G

http://www.w3.org/2001/XMLSchema#string

P304

981-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

19962

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1107039

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

365

http://www.w3.org/2001/XMLSchema#string

P50

Jesus Antonio Gonzalez-Hermosillo

P577

2011-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21870978

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation